Effect of fluoxetine on the electrocardiogram

Area of Science:

• Cardiology
• Pharmacology
• Psychiatry

Background:

• Electrocardiogram (ECG) changes are a concern with certain antidepressants.
• Tricyclic antidepressants (TCAs) like imipramine and amitriptyline are known to affect cardiac function.
• Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine have varying cardiac safety profiles.

Purpose of the Study:

• To compare the effects of fluoxetine on ECG parameters with placebo and established TCAs.
• To assess the cardiac safety profile of fluoxetine in relation to heart rate and intraventricular conduction.
• To evaluate potential differences in ECG effects between SSRIs and TCAs.

Main Methods:

• Retrospective analysis of ECG tracings from multiple drug studies.
• Blinded evaluation of ECGs to avoid bias related to drug assignment.
• Comparison of mean heart rate changes and incidence of conduction delays across treatment groups (fluoxetine, placebo, imipramine, amitriptyline, doxepin).

Main Results:

• Fluoxetine treatment was associated with a statistically significant decrease in mean heart rate.
• Imipramine and amitriptyline significantly increased heart rate; doxepin did not show a significant increase.
• Intraventricular conduction delays, including left bundle branch block, occurred in patients receiving imipramine and amitriptyline, but not in those receiving fluoxetine.

Conclusions:

• Fluoxetine demonstrates a favorable cardiac safety profile compared to imipramine and amitriptyline, with no observed intraventricular conduction delays.
• Fluoxetine's effect on heart rate (a decrease) differs from the heart rate increase associated with some TCAs.
• These findings suggest that fluoxetine may be a safer option regarding cardiac conduction in patients requiring antidepressant treatment.